Expression of c-Myc and Fas correlates with perineural invasion of pancreatic cancer

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 4, 2012, Pages 339-346

  He, Chengzhi ^a,b   Jiang, Hua ^a   Geng, Shasha ^a   Sheng, Haihui ^c   Shen, Xiaoying ^c   Zhang, Xiaoyan ^c   Zhu, Shizhang ^c   Chen, Ximei ^b   Yang, Changqing ^b   Gao, HengJun ^b,c  

^a Tongji University   (China)

^b TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^c National Engineering Center for Biochip   (China)

Author keywords

C Myc; Fas; Pancreatic cancer; Perineural invasion; Tissue microarrays

Indexed keywords

FAS ANTIGEN; FAS PROTEIN, HUMAN; FIXATIVE; FORMALDEHYDE; MYC PROTEIN; MYC PROTEIN, HUMAN; PARAFFIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CHEMISTRY; CHI SQUARE DISTRIBUTION; CHINA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PERIPHERAL NERVE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TISSUE FIXATION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CHI-SQUARE DISTRIBUTION; CHINA; FEMALE; FIXATIVES; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PARAFFIN EMBEDDING; PERIPHERAL NERVES; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MYC; RISK ASSESSMENT; RISK FACTORS; TISSUE ARRAY ANALYSIS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84864305628     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Gong Z, Holly EA and Bracci PM. Survival in Population-based Pancreatic Cancer Patients: San Francisco Bay Area, 1995-1999. American Journal of Epidemiology 2011; 174: 1373-1381.
2. Jemal A, Siegel R, Xu JQ and Ward E. Cancer Statistics, 2010. Ca-a Cancer Journal for Clinicians 2010; 60: 277-300.
3. Liebig C, Ayala G, Wilks JA, Berger DH and Albo D. Perineural invasion in cancer: a review of the literature. Cancer 2009; 115: 3379-3391.
4. Koide N, Yamada T, Shibata R, Mori T, Fukuma M, Yamazaki K, Aiura K, Shimazu M, Hirohashi S, Nimura Y and Sakamoto M. Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clinical Cancer Research 2006; 12: 2419-2426.
5. Bapat AA, Hostetter G, Von Hoff DD and Han H. Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer 2011; 11: 695-707.
6. Li YJ, Wei ZM, Meng YX and Ji XR. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol 2005; 11: 2117-2123.
7. Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, Zanucco E, Castro I and Potapenko T. Myc Is a Metastasis Gene for Non-Small-Cell Lung Cancer. Plos One 2009; 4: e6029.
8. Tsiatis AC, Herceg ME, Keedy VL, Halpern JL, Holt GE, Schwartz HS and Cates JM. Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma. Mod Pathol 2009; 22: 1432-1438.
9. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H and Bleyl U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol 2002; 15: 462-469.
10. Myong NH. Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions. Journal of Korean Medical Science 2005; 20: 770-776.
11. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, Botti C, Natali PG, Concetti A and Venanzi FM. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. International Journal of Cancer 2000; 89: 127-132.
12. Wang W-S, Chen P-M, Wang H-S, Liang W-Y and Su Y. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 2006; 27: 1113-1120.
13. Bernstorff WV, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS and Eberlein TJ. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 2002; 94: 2552-2560.
14. Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004; 4: 321-326.
15. Lin MS, Chen WC, Huang JX, Gao HJ, Zhang BF, Fang J, Zhou Q and Hu Y. Tissue Microarrays in Chinese Human Rectal Cancer: Study of Expressions of the Tumor-Associated Genes. Hepatogastroenterology 2011; 58: 1937-42.
16. Ohuchida K, Mizumoto K, Ishikawa N, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M and Tanaka M. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clinical Cancer Research 2005; 11: 7785-7793.
17. Sertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW and Efferth T. Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules 2010; 15: 2886-2910.
18. Hu FY, Wang LP, Hou LL, Yin G and Wang HC. [The expressions of STAT3, WWOX and c-myc in human non small cell lung cancer tissue and correlativity analysis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010; 26: 1203-1205, 1209.
19. Musgrove EA, Sergio CM, Anderson LR, Inman CK, McNeil CM, Alles MC, Gardiner-Garden M, Ormandy CJ, Butt AJ and Sutherland RL. Identification of downstream targets of estrogen and c-myc in breast cancer cells. Adv Exp Med Biol 2008; 617: 445-451.
20. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG and Srivastava S. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348-5353.
21. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, Conner EA, Factor VM, Roskams T and Thorgeirsson SS. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Research 2009; 69: 2775-2782.
22. Mazur PK, Einwachter H, Lee M, Sipos B, Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Kloppel G, Schmid RM and Siveke JT. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 13438-13443.
23. Vita M and Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Seminars in Cancer Biology 2006; 16: 318-330.
24. Robinson K, Asawachaicharn N, Galloway DA and Grandori C. c-Myc accelerates S-phase and requires WRN to avoid replication stress. Plos One 2009; 4: e5951.
25. Skoudy A, Hernandez-Munoz I and Navarro P. Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc. J Gastrointest Cancer 2011; 42: 76-84.
26. Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G, Gress TM and Ellenrieder V. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 2006; 25: 3714-3724.
27. Nijkamp MW, Hoogwater FJH, Steller EJA, Westendorp BF, van der Meulen TA, Leenders MWH, Borel Rinkes IHM and Kranenburg O. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. Journal of Hepatology 2010; 53: 1069-1077.
28. Tang D, Lotze MT, Kang R and Zeh HJ. Apoptosis promotes early tumorigenesis. Oncogene 2011; 30: 1851-1854.
29. Abiatari I, DeOliveira T, Kerkadze V, Schwager C, Esposito I, Giese NA, Huber P, Bergman F, Abdollahi A, Friess H and Kleeff J. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Molecular Cancer Therapeutics 2009; 8: 1494-1504.
30. Hoogwater FJH, Nijkamp MW, Smakman N, Steller EJA, Emmink BL, Westendorp BF, Raats DAE, Sprick MR, Schaefer U, Van Houdt WJ, De Bruijn MT, Schackmann RCJ, Derksen PWB, Medema JP, Walczak H, Rinkes IHMB and Kranenburg O. Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells. Gastroenterology 2010; 138: 2357-2367.
31. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Grone HJ, Ganten TM, Sultmann H, Tuttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C and Martin-Villalba A. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008; 13: 235-248.
32. Wisniewski P, Ellert-Miklaszewska A, Kwiatkowska A and Kaminska B. Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NFkappaBTIMP-2 pathway. Cell Signal 2010; 22: 212-220.
33. Bebenek M, Dus D and Kozlak J. Fas and Fas ligand as prognostic factors in human breast carcinoma. Medical Science Monitor 2006; 12: Cr457-Cr461.